A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck
The Liverpool Head and Neck Oncology Group Summary We describe a phase III trial on 200 patients with end stage squamous cell carcinoma of the head and neck. The patients were randomised to one of four treatment arms: cisplatinum alone, methotrexate alone, cisplatinum + 5-FU and cisplatinum + methotrexate. There was no significant difference in the response rates, but the survival of the cisplatinum arm was significantly better than that of the methotrexate arm. The survival of patients receiving cisplatinum as a single agent was longer than that of patients receiving cisplatinum in combination with methotrexate or 5-FU, but not significantly so. Nausea/vomiting and anaemia were significantly more common in the cisplatinum arms than in the methotrexate arm, but the toxicity of combination regimens was not significantly greater than that of cisplatinum used as a single agent.
Chemotherapy can be used in the treatment of squamous carcinoma of the head and neck, either as an adjuvant to surgery or radiotherapy, or for the sole treatment of end stage disease (that is advanced or recurrent tumours).
Methotrexate was previously regarded as the standard chemotherapeutic agent for end stage disease and its dosage and mode of administration have been extensively investigated in phase II studies. Weekly administration of 40-60 mg m 2 produces the best response rates; higher dosage and/or more frequent administration does not improve the rate or duration of response (Muggia et al., 1980) . Cisplatinum has been shown to have antitumour activity in squamous cell carcinoma of the head and neck (Jacobs et al., 1980; Wittes et al., 1979) . In one of the few randomised trials undertaken cisplatinum achieved similar response rates (23.5% and 28.6% respectively) to methotrexate in patients with recurrent head and neck cancer (Hong et al., 1983) .
Several studies using combination chemotherapy suggest that cisplatinum in combination is superior to cisplatinum alone. High dose bolus cisplatinum plus 120h continuous infusion of 5-fluorouracil every 3 weeks achieves a 70% objective response rate (26% complete responses) in end stage disease (Decker et al., 1983; Kish et al., 1984) . The importance of the timing is also emphasised. In a randomised study using equitoxic doses, 5-FU given as a continuous infusion produced a 72% response rate, but when given as a bolus injection on days 1 and 8 the response rate dropped to 20% (Kish et al., 1985) .
Only two randomised trials have been conducted to assess the value of cisplatinum as a single agent compared with cisplatinum in combination. A previous prospective randomised trial carried out in this department on end stage patients compared cisplatinum, bleomycin, cisplatinum + bleomycin and a control untreated group (Morton et al., 1985) .
Although there was no significant difference in the response rates of the three treated arms, cisplatinum as a single agent significantly prolonged the median survival time compared with the other groups. A randomised phase III trial of cisplatinum with and without methotrexate showed that methotrexate merely increased the toxicity but not the survival (Jacobs et al., 1983) .
We now report a prospective randomised phase III trial comparing cisplatinum, methotrexate, cisplatinum + 5-fluorouracil and cisplatinum + methotrexate. There was no control (untreated) arm as we have already shown that cisplatinum as a single agent significantly prolongs survival in this group of patients (Morton et al., 1985) . The patients' performance status was classified by Karnofksy's criteria (Karnofsky & Buckenall, 1949) . The data are shown in Table I 
Randomisation
The method of 'intention to treat' was followed, i.e. first all patients presenting with end stage disease were randomised to the various treatment groups before assessment of fitness and obtaining of consent; second no patient was withdrawn from analysis once he had been randomised, even if he During the infusion of cisplatinum, patients were given Maxolon (metoclopramide) at 5 mg kg-' diluted in 500 ml of normal saline. The cisplatinum infusion was stopped for 15 min every 2 h while the Maxolon infusion was given. Following the cisplatinum the patients were post-hydrated with 1 litre of normal saline in 8 h.
Methotrexate was given by intravenous bolus injection, at a dose of 40 mg m-2. 5-Fluorouracil was given at a dose of 1000 mg m-2 for 4 days as a continuous infusion, each day's dose being given in 2 litres of normal saline. This infusion followed the cisplatinum immediately and replaced the posthydration.
All of the cisplatinum containing regimens were repeated at monthly intervals, whereas methotrexate was given every 2 weeks.
Assessment during the trial During treatment we attempted to see all patients at 2-weekly intervals to assess the response, the patients' general condition and any specific symptoms, and to alter any medications. An FBC and an SMAC (urea, electrolytes and LFTs) were done on all patients. In addition to this patients receiving cisplatinum had a chest X-ray, ECG, pure tone audiometry and 24 h urinary creatinine clearance before each course of treatment. If the creatinine clearance fell to between 50 and 60 ml min-' the dose of cisplatinum was reduced to 50 mg m-2. If it fell below 50 ml min ' treatment was postponed until the creatinine clearance returned to normal. Treatment was not given when the haematological indices were unsatisfactory. 
Assessment of response
The WHO definition of response was used (Miller et al., 1981) . Accessible lesions of the mouth and nodes in the neck were measured by calipers. Assessment of laryngeal and hypopharyngeal lesions was mainly based on clinical examination. Lesions of the nose, sinus, nasopharynx and ear were assessed by radiology. Toxicity Toxicity was assessed after each course of chemotherapy. The data are displayed according to the WHO criteria (Miller et al., 1981) .
Informed consent
Ethical committee approval was obtained for the trial. The trial, its purpose and side-effects of the chemotherapy were discussed fully with each patient and his or her relatives.
Follow-up and analysis of the data The exact date of death of those who have died is known either from personal follow-up or from the Mersey Region Cancer Registry. The status of the patients who are alive has been checked within, at most, the past 6 weeks. No patient has been lost to follow-up.
Qualitative data are displayed in contingency tables and analysed by X2. Survival is presented by the Kaplan-Meier method (Kaplan & Meier, 1985) . Differences between survival curves were analysed by the log rank test (Peto et al., 1976) . Prognostic factors were identified by Cox's regression analysis (Cox, 1972) .
Results

Response rate
The response rates are shown in Table II . The response rate for the whole group was 21.5%, and for treated patients was 27.8%. There was no significant difference in the response rate between the various arms, either of the whole group (X29 = 14.42) or of the treated group (X26 = 6.99) The response rate for previously untreated patients was 35% (19/55). (Table VII) .
Mild reduction of white cell count (WHO 1-2) affected 8% of patients receiving cisplatinum, and 3% of patients receiving methotrexate. These differences were not significant. Severe toxicity (WHO 3-4) was rare (0.5% of the whole series) (Table VIII) .
Mild reduction of platelets (WHO 1-2) was unusual (2.1% of the whole group) and severe reduction rare (0.2%). There was no significant difference between the arms (Table IX) .
Many other indices were routinely monitored but the number of patients recording any abnormalities was very small. Table X summarises these indices. No. of courses given 
Discussion
This randomised trial was designed to assess whether treatment of advanced or recurrent head and neck cancer with cisplatinum alone could produce a survival advantage over methotrexate alone, and whether the addition of methotrexate or 5-FU to cisplatinum would have any benefit. However, we have also looked at response rates, and at the toxicity of the regimens used.
Our response rates are rather poor when compared with the excellent results of others. In particular our response rate of 30% to cisplatinum + 5-FU compares badly with that of Kish et al. (1984) , who achieved an overall response rate of 70%, using the same treatment regime. This can perhaps be explained by the patients' general condition. In Kish et al.'s study, 80% of patients had a performance status of better than 70 whereas only 63% in our series were in good condition.
There was no significant difference in the response rates of the four groups. However, this is probably a type II error related to the large number of patients needed to produce a significant result if response is the sole criterion. Our survival analysis showed that cisplatinum as a single agent was better than methotrexate, and superior also to cisplatinum in combination with 5-FU or methotrexate, although not significantly so. This is contrary to the present climate of opinion, which favours a search for combination regimens. However, no phase III trial has yet demonstrated that combination regimens achieve a better survival than single agent cisplatinum.
We have not stratified our patients for prognostic factors. Many statisticians now agree that the benefits of this method are not great (Peto et al., 1976) , and that multivariate analysis should be used to identify prognostic factors. Using Cox's multivariate regression analysis we confirmed the findings of univariate analysis that the only significant factors were Karnofsky performance status and response to chemotherapy. Other factors, such as age, sex, site of the tumour and histological grade were not significant prognostic factors. It seems that every trial/study of chemotherapy in head and neck cancer produces a different set of significant prognostic factors (Amer et al., 1980; Bertino et al., 1975; Campbell et al., 1987; Siodlak et al., 1989; Vogel & Kaplan, 1979; Wolf et al., 1984) , probably because these factors are being confounded by other as yet unidentified factors concerned with cell growth and behaviour, for example tumour DNA content (ploidy) (Goldsmith et al., 1986) and oncogene expression (Field et al., 1986) .
Methotrexate is clearly a less toxic compound than cisplatinum, although it was surprising to find no increased toxicity in combination regimens compared with cisplatinum alone. The explanation might be that the toxicity categories in the WHO scale are rather liberal. Even if combination regimens do not increase toxicity they inevitably increase cost. This is particularly true of the cisplatinum + 5-FU regimen, which requires five extra days in hospital. This adds a further £1500 (at 1988 prices) to the cost of treatment. In the complete absence of any survival benefit this extra cost cannot be justified.
We did not attempt to assess symptom scores in this group of patients. Most of them had already received extensive treatment and their quality of life is already so low that meaningful differences are very hard to detect and measure. One measure of the quality of life is the proportion of patients surviving beyond six months. There are two reasons for this: first, untreated patients rarely survive beyond this time interval (Morton et al., 1985) ; and second, six courses of treatment with the recovery period after each course produces a period of 6 months when the quality of life is very low. In order to benefit the patient must survive beyond this period in reasonable condition, and preferably beyond 1 year. Fifty-two per cent of patients randomised to receive cisplatinum survived beyond 6 months, whereas 31 % of patients in the methotrexate arm survived beyond this time. Only the patient can decide whether this extra survival is worth the increased morbidity of chemotherapy.
